Asset profile
petrelintide
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2028-10-20.
ZUPREME (NCT06662539): The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 12 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Petrelintide: this drug | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| AZD6234 | Phase 3 | Peptide | Amylin receptor | ||
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Eloralintide | Phase 3 | Peptide | Amylin receptor | ||
| MET-097i | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | ||
| GUB-UCN2 | Phase 1/2 | Peptide | Amylin receptor | ||
| MET-233i | Phase 1/2 | Peptide | Amylin receptor | ||
| RM-718 | Phase 1/2 | Peptide | Amylin receptor | ||
| BGM1812 | Phase 1 | Peptide | Amylin/calcitonin receptor (dual) | ||
| GUB014295 | Phase 1 | Peptide | Amylin receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
6 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (2)
2030 (1)
July 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.